Benefit of Adjuvant Atezolizumab in PD-L1-Positive Early-Stage NSCLC

Benefit of Adjuvant Atezolizumab in PD-L1-Positive Early-Stage NSCLC

Around 30% of patients with non-small cell lung cancer (NSCLC) are diagnosed with early-stage disease and undergo surgery with curative intent. After...

Novel Immunotherapy Combo For Untreated Advanced Melanoma

Novel Immunotherapy Combo For Untreated Advanced Melanoma

Immunotherapy with immune checkpoint inhibitors (ICIs) has transformed the outlook for patients with advanced melanoma. In order to optimize the benefit/risk profile...

Toripalimab Enhances Chemotherapy Efficacy in Advanced Nasopharyngeal Cancer

Toripalimab Enhances Chemotherapy Efficacy in Advanced Nasopharyngeal Cancer

Nasopharyngeal cancer (NPC) is a relatively rare malignancy in Western countries, but it is endemic in Southern China and Southeast Asia. Due...

Survival Benefit With Novel PSMA-Targeted Radioligand in Metastatic CRPC

Survival Benefit With Novel PSMA-Targeted Radioligand in Metastatic CRPC

Despite advances in the management of castration-resistant prostate cancer (CRPC) and availability of several therapeutic options with the potential to prolong survival,...

Adjuvant Immunotherapy: A Practice-Changing Strategy in RCC

Adjuvant Immunotherapy: A Practice-Changing Strategy in RCC

For patients with locoregional renal cell carcinoma (RCC), surgery (nephrectomy) is the standard of care and is potentially curative. However, nearly half...

Adjuvant Olaparib New Standard for BRCA-Mutated Breast Cancer

Adjuvant Olaparib New Standard for BRCA-Mutated Breast Cancer

Due to the ongoing COVID-19 pandemic, the American Society of Clinical Oncology (ASCO) Annual Meeting was held virtually for the second year...